查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1828145

2025年肝癌诊断全球市场报告

Liver Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，肝癌诊断市场规模强劲成长，从2024年的96.9亿美元增加至2025年的103.2亿美元，复合年增长率为6.5%。这段时期的成长可归因于切片检查技术和组织病理学的发展、生物标记检测、筛检方案的不断改进、基因检测的进步以及肝臟影像技术的改进。

预计未来几年肝癌诊断市场将强劲成长，到2029年将达到137.1亿美元，年复合成长率（CAGR）为7.4%。预测期内的成长可归因于监管变化和标准化、成像模式日益重要、次世代定序仪的发展、筛检项目的扩展和认知度提升，以及对基于生物标誌物的检测需求的不断增长。预测期内的主要趋势包括发病率和盛行率的上升、影像技术的进步、对非侵入性诊断、精准医疗和个人化诊断的关注，以及人工智慧 (AI) 的整合。

肝癌诊断涵盖多种用于识别和评估肝癌（一种起源于肝臟的恶性肿瘤）的技术。这些方法结合影像检查和分子检测，在肝癌的早期发现和诊断中发挥重要作用。

肝细胞癌、胆管癌、肝母细胞瘤及其他相关类型是肝癌诊断中的主要癌症类型。肝细胞癌 (HCC) 尤其重要，因为它是影响有肝硬化或慢性肝病病史人群的主要肝癌类型。筛检方法包括临床检测、影像学检查、内视镜检查和切片检查。萤光原位杂交 (FISH)、比较基因组杂合反应(CGH) 和免疫组织杂合反应(IHC) 等多种技术被用于各种终端用途，包括医院和诊断实验室、学术和研究机构以及製药和合约研究组织 (CRO) 实验室。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要医疗设备重新认证，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供肝癌诊断市场统计数据，包括全球市场规模、区域份额、肝癌诊断市场份额竞争对手、详细的肝癌诊断细分市场、市场趋势和商业机会，以及您在肝癌诊断行业取得成功所需的数据。本肝癌诊断市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

未来五年7.4%的预测成长率比我们先前对该市场的预测略有下降，下降了0.1%。下降的主要原因是美国与其他国家之间关税的影响。这种影响可能会直接影响到美国，因为甲胎蛋白酵素结合免疫吸附检测法（AFP ELISA）检测套组和造影超音波的供应链中断，这些试剂盒和探头来自爱尔兰和巴西等主要地区，这可能导致肝细胞癌的检测延迟和诊断成本的增加。由于互惠关税以及贸易紧张局势和限制措施加剧对全球经济和贸易的负面影响，这种影响可能会更加广泛。

肝癌盛行率的预期成长将推动肝癌诊断市场的成长。肝癌的特征是肝细胞不受控制地增殖，会造成严重的健康风险。肝癌诊断测试在确定原发性肝癌确诊后癌细胞在肝内或肝周围扩散的程度方面发挥重要作用。根据美国癌症协会的报告，女性肝癌和肝内胆管癌新病例呈上升趋势，到 2023 年美国将达到 13,230 例。预计 2023 年美国新发肝癌病例总数将达 41,210 例，造成 29,380 人死亡。这凸显了随着肝癌盛行率的上升，对肝癌诊断的迫切需求。

乙肝的日益流行预计将进一步推动肝癌诊断市场的发展。乙肝是一种病毒性感染疾病侵袭肝臟，并可引起急性和慢性症状。对于慢性B型肝炎患者，定期监测对于评估肝臟健康状况、发现肝损伤或癌症征兆至关重要。根据美国疾病管制与预防中心的数据，全球约有2.96亿人感染B肝，其中包括超过600万五岁以下儿童。乙肝疫情的日益蔓延是肝癌诊断市场扩张的关键因素。

肝癌诊断市场的主要企业正在开发基于生物标记的先进检测方法和演算法，以提高诊断准确性并促进早期发现。基于生物标记的检测方法和演算法是使用特定生物标记来识别疾病的诊断工具，可提供更准确、更有效率的诊断能力。例如，美国生技公司罗氏诊断于2023年11月推出了Elecsys PIVKA-II检测方法和Elecsys GAAD演算法。 Elecsys PIVKA-II检测方法透过识别与肝细胞癌（HCC）相关的升高的PIVKA-II生物标记来改善高风险患者肝癌的早期检测。同时，Elecsys GAAD演算法结合了包括PIVKA-II和AFP在内的各种诊断标记物，以提高诊断准确性并简化肝癌检测的决策。

2023年4月，美国生技公司Integrated DNA Technologies收购了Archer NGS研究检测技术，收购金额未揭露。此次收购旨在增强Integrated DNA Technologies在次世代定序仪(NGS)领域的产品组合，重点在于拓展研究能力并加强基因组研究的检测开发。 Archer, Inc.是美国一家知名的肝癌诊断解决方案提供者。

2022年12月，FUJIFILM Holdings公司收购了肿瘤资讯学和医疗IT解决方案提供商Inspirata，收购金额未揭露。此次收购涵盖Dynamyx的数位病理技术，并将Inspirata的员工和客户整合到FUJIFILM。这项策略性倡议使FUJIFILM能够扩展其Synapse Enterprise Imaging产品组合，并透过将病理数据和图像整合到其电子健康记录系统中，简化癌症患者治疗和支持护理团队。

肝癌诊断市场的主要企业包括雅培实验室、罗氏公司、Qiagen NV、赛默飞世尔科技公司、西门子医疗、Illumina公司、荷兰皇家飞利浦公司、Epigenomics AG、Digna Biotech SL、Biocept、丹纳赫医疗公司、Foundation Medicine公司、安默伦科技公司、Genetechnoon、Fantechdance公司、Foundation FUJIFILM Medical、安Diagnostics公司、Oxford Gene Technology公司、徕卡生物系统-纽斯洛赫有限公司、Exicon AS、BioGenex Laboratories公司、OncoCyte公司、Guardant Health公司、Exact Sciences公司、Grail公司、FreeNorm Holdings公司、Natera公司、Personal Genome Diagnostics公司和Thrive Ear Detection。

2024 年，北美是肝癌诊断市场最大的地区。肝癌诊断市场报告涵盖的地区包括亚太地区、西欧、东欧、北美、南美以及中东和非洲。

肝癌诊断市场报告涵盖的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国、美国、加拿大、义大利、西班牙

肝癌诊断市场包括营业单位透过肝臟移植、 电脑断层扫描和肝功能检查产生的收益。市场价值包括服务供应商销售或包含在其服务产品中的相关产品的价值。肝癌诊断市场还包括用于提供肝癌诊断服务的体外和影像工具、人工智慧工具和机器学习工具的销售。该市场的价值是指「工厂门口」价值，即商品製造商或创造者出售给其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接出售给最终客户的商品价值。该市场中的商品价值还包括商品创造者出售的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球肝癌诊断：PESTEL分析（政治、社会、科技、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球肝癌诊断市场：成长率分析
  • 全球肝癌诊断市场表现：规模与成长，2019-2024
  • 全球肝癌诊断市场预测：规模与成长，2024-2029年，2034年
  • 全球肝癌诊断：总目标市场（TAM）

第六章 市场细分

  • 全球肝癌诊断市场：依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 肝细胞癌
  • 胆管癌
  • 肝母细胞瘤
  • 其他类型
  • 全球肝癌诊断市场：按筛检类型、表现和预测，2019-2024 年、2024-2029 年、2034 年
  • 实验室检查
  • 影像学
  • 内视镜检查
  • 切片检查
  • 其他筛检
  • 全球肝癌诊断市场：依技术、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 萤光原位杂合反应（FISH）
  • 比较基因组杂合反应（CGH）
  • 免疫组织化学（IHC）
  • 其他技术
  • 全球肝癌诊断市场最终用途、绩效及预测（2019-2024、2024-2029、2034）
  • 医院和诊断实验室
  • 学术研究机构
  • 製药/CRO实验室
  • 全球肝癌诊断市场：肝细胞癌（类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 早期肝细胞癌
  • 晚期肝细胞癌
  • 全球肝癌诊断市场：依胆管癌类型细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 肝内胆管癌
  • 肝外胆管癌
  • 全球肝癌诊断市场：肝母细胞瘤类型细分、绩效及预测（2019-2024、2024-2029、2034）
  • 纯肝母细胞瘤
  • 混合性肝母细胞瘤
  • 全球肝癌诊断市场：按类型、其他、绩效和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 次发性肝癌
  • 纤维板层癌

第七章 区域和国家分析

  • 全球肝癌诊断市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球肝癌诊断市场：依国家、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 肝癌诊断市场：竞争格局
  • 肝癌诊断市场：公司简介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Illumina Inc.
  • Koninklijke Philips NV
  • Epigenomics AG
  • Digna Biotech SL
  • Biocept Inc.
  • Danaher Corporation
  • Foundation Medicine Inc.
  • Agilent Technologies Inc.
  • Genemed Biotechnologies Inc.
  • Merck KGaA
  • Fujifilm Medical Systems USA Inc.
  • GE Healthcare
  • Advanced Cell Diagnostics Inc.
  • Oxford Gene Technology
  • Leica Biosystems Nussloch GmbH

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029 年肝癌诊断市场：提供新机会的国家
  • 2029 年肝癌诊断市场：细分市场将带来新机会
  • 2029年肝癌诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r24276u

Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.

Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The liver cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $9.69 billion in 2024 to $10.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to biopsy techniques and histopathology, development of biomarker detection, evolution of screening programs, advances in genetic testing, improvements in liver imaging modalities.

The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $13.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to regulatory changes and standardization, growing importance of imaging modalities, development of next-generation sequencing, expanded screening programs and awareness, rising demand for biomarker-based testing. Major trends in the forecast period include rise in incidence and prevalence, advancements in imaging technologies, focus on non-invasive diagnostics, precision medicine and personalized diagnostics, integration of artificial intelligence (AI).

The forecast of 7.4% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for alpha-fetoprotein enzyme-linked immunosorbent assay (AFP ELISA) test kits and contrast-enhanced ultrasound probes, sourced from key regions such as Ireland and Brazil, which could lead to delayed hepatocellular carcinoma detection and higher diagnostic expenses.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.

The growing prevalence of hepatitis B is anticipated to further boost the liver cancer diagnostics market. Hepatitis B, a viral infection affecting the liver, can lead to both acute and chronic conditions. Regular monitoring is essential for individuals with chronic hepatitis B to assess liver health and detect signs of liver damage or cancer. According to the Centers for Disease Control and Prevention, approximately 296 million people, including over 6 million children under the age of 5, are affected by hepatitis B. This growing prevalence of hepatitis B is a significant driver for the expansion of the liver cancer diagnostics market.

Key companies in the liver cancer diagnostics market are creating advanced biomarker-based assays and algorithms to enhance diagnostic accuracy and facilitate early detection. Biomarker-based assays and algorithms are diagnostic tools that employ specific biological markers to identify diseases, offering more precise and efficient diagnostic capabilities. For example, in November 2023, Roche Diagnostics, a U.S.-based biotech corporation, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving early liver cancer detection in high-risk patients. Meanwhile, the Elecsys GAAD algorithm combines various diagnostic markers, including PIVKA-II and AFP, to enhance diagnostic accuracy and streamline decision-making in liver cancer detection.

In April 2023, Integrated DNA Technologies, a U.S.-based biotechnology company, acquired Archer NGS research assays for an undisclosed sum. This acquisition was intended to strengthen Integrated DNA Technologies' portfolio in next-generation sequencing (NGS), with a focus on expanding its research capabilities and enhancing assay development for genomic research. Archer, Inc. is recognized as a U.S. provider of diagnostic solutions for liver cancer.

In December 2022, Fujifilm Holdings Corporation acquired Inspirata, an oncology informatics and healthcare IT solutions provider, for an undisclosed amount. The acquisition included Dynamyx digital pathology technology and involved the integration of Inspirata's staff and clients into Fujifilm. This strategic move allows Fujifilm to expand its Synapse Enterprise Imaging portfolio, incorporating pathology data and images into electronic medical record systems to streamline cancer patient treatment and support care teams.

Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liver cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatoblastoma; Other Types
  • 2) By Screening: Laboratory Testing; Imaging; Endoscopy; Biopsy; Other Screenings
  • 3) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
  • 4) By End Use: Hospitals And Diagnostic Laboratories; Academic And Research Institutes; Pharmaceutical And CRO Laboratories
  • Subsegments:
  • 1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma; Advanced-Stage Hepatocellular Carcinoma
  • 2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma
  • 3) By Hepatoblastoma: Pure Hepatoblastoma; Mixed Hepatoblastoma
  • 4) Other Types: Secondary Liver Cancer; Fibrolamellar Carcinoma
  • Companies Mentioned: Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Qiagen NV; Thermo Fisher Scientific Inc.; Siemens Healthineers; Illumina Inc.; Koninklijke Philips NV; Epigenomics AG; Digna Biotech SL; Biocept Inc.; Danaher Corporation; Foundation Medicine Inc.; Agilent Technologies Inc.; Genemed Biotechnologies Inc.; Merck KGaA; Fujifilm Medical Systems USA Inc.; GE Healthcare; Advanced Cell Diagnostics Inc.; Oxford Gene Technology; Leica Biosystems Nussloch GmbH; Exiqon A/S; BioGenex Laboratories Inc.; OncoCyte Corporation; Guardant Health Inc.; Exact Sciences Corporation; Grail Inc.; Freenome Holdings Inc.; Natera Inc.; Personal Genome Diagnostics Inc.; Thrive Earlier Detection Corp
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liver Cancer Diagnostics Market Characteristics

3. Liver Cancer Diagnostics Market Trends And Strategies

4. Liver Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Liver Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Liver Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Liver Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Liver Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Liver Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Liver Cancer Diagnostics Total Addressable Market (TAM)

6. Liver Cancer Diagnostics Market Segmentation

  • 6.1. Global Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Hepatoblastoma
  • Other Types
  • 6.2. Global Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory Testing
  • Imaging
  • Endoscopy
  • Biopsy
  • Other Screenings
  • 6.3. Global Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fluorescent In Situ Hybridization (FISH)
  • Comparative Genomic Hybridization (CGH)
  • Immunohistochemical (IHC)
  • Other Technologies
  • 6.4. Global Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Diagnostic Laboratories
  • Academic And Research Institutes
  • Pharmaceutical And CRO Laboratories
  • 6.5. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Hepatocellular Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Early-Stage Hepatocellular Carcinoma
  • Advanced-Stage Hepatocellular Carcinoma
  • 6.6. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Cholangiocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intrahepatic Cholangiocarcinoma
  • Extrahepatic Cholangiocarcinoma
  • 6.7. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Hepatoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pure Hepatoblastoma
  • Mixed Hepatoblastoma
  • 6.8. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Secondary Liver Cancer
  • Fibrolamellar Carcinoma

7. Liver Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Liver Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Liver Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liver Cancer Diagnostics Market

  • 8.1. Asia-Pacific Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liver Cancer Diagnostics Market

  • 9.1. China Liver Cancer Diagnostics Market Overview
  • 9.2. China Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liver Cancer Diagnostics Market

  • 10.1. India Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liver Cancer Diagnostics Market

  • 11.1. Japan Liver Cancer Diagnostics Market Overview
  • 11.2. Japan Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liver Cancer Diagnostics Market

  • 12.1. Australia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liver Cancer Diagnostics Market

  • 13.1. Indonesia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liver Cancer Diagnostics Market

  • 14.1. South Korea Liver Cancer Diagnostics Market Overview
  • 14.2. South Korea Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liver Cancer Diagnostics Market

  • 15.1. Western Europe Liver Cancer Diagnostics Market Overview
  • 15.2. Western Europe Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liver Cancer Diagnostics Market

  • 16.1. UK Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liver Cancer Diagnostics Market

  • 17.1. Germany Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liver Cancer Diagnostics Market

  • 18.1. France Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liver Cancer Diagnostics Market

  • 19.1. Italy Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liver Cancer Diagnostics Market

  • 20.1. Spain Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liver Cancer Diagnostics Market

  • 21.1. Eastern Europe Liver Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liver Cancer Diagnostics Market

  • 22.1. Russia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liver Cancer Diagnostics Market

  • 23.1. North America Liver Cancer Diagnostics Market Overview
  • 23.2. North America Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liver Cancer Diagnostics Market

  • 24.1. USA Liver Cancer Diagnostics Market Overview
  • 24.2. USA Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liver Cancer Diagnostics Market

  • 25.1. Canada Liver Cancer Diagnostics Market Overview
  • 25.2. Canada Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liver Cancer Diagnostics Market

  • 26.1. South America Liver Cancer Diagnostics Market Overview
  • 26.2. South America Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liver Cancer Diagnostics Market

  • 27.1. Brazil Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liver Cancer Diagnostics Market

  • 28.1. Middle East Liver Cancer Diagnostics Market Overview
  • 28.2. Middle East Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liver Cancer Diagnostics Market

  • 29.1. Africa Liver Cancer Diagnostics Market Overview
  • 29.2. Africa Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liver Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Liver Cancer Diagnostics Market Competitive Landscape
  • 30.2. Liver Cancer Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

31. Liver Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Illumina Inc.
  • 31.2. Koninklijke Philips NV
  • 31.3. Epigenomics AG
  • 31.4. Digna Biotech SL
  • 31.5. Biocept Inc.
  • 31.6. Danaher Corporation
  • 31.7. Foundation Medicine Inc.
  • 31.8. Agilent Technologies Inc.
  • 31.9. Genemed Biotechnologies Inc.
  • 31.10. Merck KGaA
  • 31.11. Fujifilm Medical Systems USA Inc.
  • 31.12. GE Healthcare
  • 31.13. Advanced Cell Diagnostics Inc.
  • 31.14. Oxford Gene Technology
  • 31.15. Leica Biosystems Nussloch GmbH

32. Global Liver Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liver Cancer Diagnostics Market

34. Recent Developments In The Liver Cancer Diagnostics Market

35. Liver Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Liver Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Liver Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Liver Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer